TY-51469   Click here for help

GtoPdb Ligand ID: 9779

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: TY-51469 is a chymase inhibitor [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 203.74
Molecular weight 525.98
XLogP 3.92
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc2c(c1)c(C)c(s2)S(=O)(=O)Nc1ccc(cc1S(=O)(=O)C)c1scc(n1)C(=O)O
Isomeric SMILES Fc1ccc2c(c1)c(C)c(s2)S(=O)(=O)Nc1ccc(cc1S(=O)(=O)C)c1scc(n1)C(=O)O
InChI InChI=1S/C20H15FN2O6S4/c1-10-13-8-12(21)4-6-16(13)31-20(10)33(28,29)23-14-5-3-11(7-17(14)32(2,26)27)18-22-15(9-30-18)19(24)25/h3-9,23H,1-2H3,(H,24,25)
InChI Key CBRCULCCRGSSLB-UHFFFAOYSA-N
References
1. Liu WX, Wang Y, Sang LX, Zhang S, Wang T, Zhou F, Gu SZ. (2016)
Chymase inhibitor TY-51469 in therapy of inflammatory bowel disease.
World J Gastroenterol, 22 (5): 1826-33. [PMID:26855541]
2. Palaniyandi SS, Nagai Y, Watanabe K, Ma M, Veeraveedu PT, Prakash P, Kamal FA, Abe Y, Yamaguchi K, Tachikawa H et al.. (2007)
Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats.
Exp Biol Med (Maywood), 232 (9): 1213-21. [PMID:17895529]
3. Takato H, Yasui M, Ichikawa Y, Waseda Y, Inuzuka K, Nishizawa Y, Tagami A, Fujimura M, Nakao S. (2011)
The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice.
Exp Lung Res, 37 (2): 101-8. [PMID:21128860]